# Bristol-Myers Squibb: Phase 2 study in Early-Stage Non-Small Cell Lung Cancer (80 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) |
| NCT ID | NCT07871214 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Early-Stage Non-Small Cell Lung Cancer |
| Intervention types | drug |
| Target enrollment | 80 |
| Site countries | United States, Australia, Canada, China, France, Germany, Italy, Japan, Poland, Romania, South Korea, Spain |
| Posted | 2026-10-13 |
| Planned start | 2026-11-30 |
| Event | Newly registered study |
| Event date | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07871214). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.